{"id":"53c1644b92d7","type":"article","url":"https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/","title":"Statines voor primaire cardiovasculaire preventie: USPSTF-aanbeveling","title_en":"Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["secundaire-preventie"],"journal":"JAMA","doi":"10.1001/jama.2016.15450","source_url":"https://doi.org/10.1001/jama.2016.15450","authors":["Kirsten Bibbins-Domingo","David C Grossman","Susan J Curry","Karina W Davidson","John W Epling","Francisco A R García","Matthew W Gillman","Alex R Kemper","Alex H Krist","Ann E Kurth","C Seth Landefeld","Michael L LeFevre","Carol M Mangione","William R Phillips","Douglas K Owens","Maureen G Phipps","Michael P Pignone"],"significance":9,"published":"2016-11-15","source_date":"2016-11-15","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/preventie/statines-primaire-preventie/"],"congress":"","summary_en":"The USPSTF recommendation endorsed statin use for primary cardiovascular prevention in adults aged 40–75 with at least one CVD risk factor and a 10-year risk of 10% or greater. The guideline defined evidence-based thresholds for initiating statin therapy in adults without established cardiovascular disease.","created":"2026-07-03T10:26:24Z","updated":"2026-07-03T13:25:44Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"USPSTF-aanbeveling voor statinegebruik bij de primaire preventie van cardiovasculaire ziekte bij volwassenen. Definieert drempelwaarden en indicaties voor statine-initiatie.","abstract_original":"IMPORTANCE: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults. OBJECTIVE: To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults. EVIDENCE REVIEW: The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events. CONCLUSIONS AND RECOMMENDATIONS: The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater (B recommendation). The USPSTF recommends that clinicians selectively offer low- to moderate-dose statins to adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors and a calculated 10-year CVD event risk of 7.5% to 10% (C recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older (I statement)."}